FDA Approves GABAPENTIN — Camber Pharmaceuticals, Inc.
# FDA Approves Gabapentin Generic from Camber Pharmaceuticals The FDA has approved Camber Pharmaceuticals' abbreviated new drug application for generic gabapentin oral formulation (ANDA214956), adding another competitor to the established market for this widely prescribed neuropathic pain and seizure medication. The approval is expected to increase price competition and expand patient access to the generic alternative, further pressuring margins in the increasingly crowded gabapentin marketplace.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day